Last reviewed · How we verify

Co-trimoxazole 12 — Competitive Intelligence Brief

Co-trimoxazole 12 (Co-trimoxazole 12) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide antibiotic combination. Area: Infectious Disease.

marketed Sulfonamide antibiotic combination Dihydropteroate synthase and dihydrofolate reductase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Co-trimoxazole 12 (Co-trimoxazole 12) — Khon Kaen University. Co-trimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Co-trimoxazole 12 TARGET Co-trimoxazole 12 Khon Kaen University marketed Sulfonamide antibiotic combination Dihydropteroate synthase and dihydrofolate reductase
Trimethoprim and sulfamethoxazole Trimethoprim and sulfamethoxazole National Institute of Allergy and Infectious Diseases (NIAID) marketed Sulfonamide antibiotic combination Dihydropteroate synthase and dihydrofolate reductase
Co-trimoxazole 20 Co-trimoxazole 20 Khon Kaen University marketed Sulfonamide antibiotic combination Dihydropteroate synthase and dihydrofolate reductase
Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] Fundacion Clinic per a la Recerca Biomédica marketed Sulfonamide antibiotic combination Dihydropteroate synthase and dihydrofolate reductase
Sulfamethoxazole / Trimethoprim Injectable Product Sulfamethoxazole / Trimethoprim Injectable Product Fundacion Clinic per a la Recerca Biomédica marketed Sulfonamide + dihydrofolate reductase inhibitor combination Dihydropteroate synthase and dihydrofolate reductase
Intermittent preventive treatment:sulphadoxine-pyrimethamine Intermittent preventive treatment:sulphadoxine-pyrimethamine London School of Hygiene and Tropical Medicine phase 3 Antifolate antimalarial combination Dihydropteroate synthase and dihydrofolate reductase
Cotrimoxazole dispersible tablet Cotrimoxazole dispersible tablet University of Oxford phase 3 Sulfonamide antibiotic combination Dihydropteroate synthase and dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide antibiotic combination class)

  1. Khon Kaen University · 2 drugs in this class
  2. Department of Medical Services Ministry of Public Health of Thailand · 1 drug in this class
  3. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class
  4. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
  5. University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Co-trimoxazole 12 — Competitive Intelligence Brief. https://druglandscape.com/ci/co-trimoxazole-12. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: